NCT00046111View on ClinicalTrials.gov

A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Lung Cancer, Small CellSolid Tumor Cancer
Interventions
DRUG

topotecan

A topoisomerase I inhibitor used for ovarian and lung cancer treatment

Trial Locations (5)

10021

GSK Investigational Site, New York

19111

GSK Investigational Site, Philadelphia

37203

GSK Investigational Site, Nashville

78229

GSK Investigational Site, San Antonio

K1H 1C4

GSK Investigational Site, Ottawa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY